Panacea Biotec Limited has announced an amendment to its Letter of Award (LOA) from UNICEF for the supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive -TT® (DTwP -HepB -Hib). This amendment includes an increase in the award value. Specifically, the value for the year 2026 has been increased by US$ 2.55 million (approximately ₹23 Crore), raising the total for that year from US$ 14.25 million to US$ 16.8 million. Additionally, the value for the year 2027 has been increased by US$ 2.70 million (approximately ₹24 Crore), from US$ 12.48 million to US$ 15.18 million. Furthermore, an additional award for the supply of Easyfive -TT® worth approximately US$ 3.68 million (approximately ₹33 Crore) has been received for the year 2027. These increases bring the total amended award value for the supply of Easyfive -TT® to US$ 8.93 million (approximately ₹80 Crore), comprising US$ 2.55 million for CY2026 and US$ 6.38 million for CY2027. The original LOA was for supplies during calendar years 2023-2027. The company has disclosed this information in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The contract is with an international entity, UNICEF, and is for the supply of Pentavalent Vaccine.